Graham BEATON,Fabio C. TUCCI,Satheesh B. RAVULA,Chandravadan R. SHAH,Hiep LUU
申请号：
US16784486
公开号：
US20200181099A1
申请日:
2020.02.07
申请国别(地区):
US
年份:
2020
代理人:
摘要：
Heterocyclic compounds are described that are lysophosphatidic acid receptor ligands that are useful in the treatment of lysophosphatidic acid receptor-dependent diseases and conditions, including but not limited to diseases involving fibrosis, such as fibrosis of the heart, kidney, liver and lung, and scleroderma； inflammatory diseases such as diabetic nephropathy and inflammatory bowel disease； ocular diseases such as diseases involving retinal degeneration； nerve diseases such as pruritus and pain. Non-limiting examples of those compounds include (RS)-3-Cyclopropyl-2-{4-[3-methyl-4-((R)-1-phenyl-ethoxycarbonylamino)-isoxazol-5-yl]-benzyloxy}-propionic acid and (R)-1-(4′；-{5-[1-(2-Chloro-phenyl)-ethoxycarbonylamino]-4-fluoro-pyrazol-1-yl}-2-fluoro-biphenyl-4-yl)-cyclopropanecarboxylic acid.
